Vera Therapeutics (VERA) announced the appointment of Christopher Hite to Vera Therapeutics’ Board of Directors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- 3 Best Stocks With 125%+ Upside Ahead, According to Top Analysts, 3/2/2026
- Vera Therapeutics price target raised to $110 from $90 at H.C. Wainwright
- Vera Therapeutics: Strong Atacicept Phase 3 Data and Favorable Regulatory, Commercial Setup Support Buy Rating
- Undervalued IgAN Opportunity: Buy Rating on VERA Driven by Atacicept’s Robust ORIGIN 3 Data and Long-Term Kidney Disease Upside
- Vera Therapeutics: Buy Rating Backed by Strong Atacicept Data, Robust Cash Runway, and Large IgAN Market Opportunity